Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broad-spectrum antibiotics added to corticosteroids for pediatric acute severe ulcerative colitis
2015-001900-76Phase 3Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Sep 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amoxicillin, doxycycline, vancomycin, metronidazole and methylprednisolone in autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Total PUCAI score at day 5. Started Sep 2021; status: active.
02
Drugs
amoxicillindoxycyclinevancomycinmetronidazolemethylprednisolone
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2015-001900-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001900-76.